GeneMatrix

What GeneMatrix does

GeneMatrix (Genematrix Inc.) is a South Korea-based molecular diagnostics company founded in 2000 and listed on KOSDAQ (ticker: 109820) since 2009. The company develops and sells the NeoPlex™ line of multiplex real-time PCR diagnostic kits built on its proprietary C-Tag™ technology, which enables simultaneous detection of up to 20 pathogen targets in a single tube. The product portfolio spans sexually transmitted infections (STI-7, STI-7 PLUS, STI-14), human papillomavirus (HPV29 and HPV HR), respiratory infections (RV-Panel A for 10 viruses, RV-Panel B for 9 viruses, RB-8 for 8 bacteria, FluCOVID, COVID-19 FAST), tuberculosis (TB/NTM-5), and gastrointestinal infections (GI-Virus 6). Beyond C-Tag™, the technology stack includes EnCleap™ primer technology for non-specific amplification suppression, TriO™ for high-sensitivity subtype detection, and RFMP™ MALDI-TOF genotyping.

GeneMatrix serves clinical laboratories, hospitals, and reference laboratories globally, with distribution concentrated in Asia (Korea), Europe (post-CE-IVDR certification), the Middle East (Dubai via Medlab), and North America (post-FDA EUA). Revenue is generated primarily through one-time sales of diagnostic kits in standardized formats (96 tests/kit, 50 tests/kit) via direct website inquiries and international exhibition channels; biochemical diagnostic reagents are sold through the wholly-owned HBI subsidiary (HiSens™ brand) acquired in 2011. The company also operates a vaccine development pipeline of six candidates (hepatitis A, Japanese encephalitis, herpes zoster, COVID-19, Zika, HPV therapeutic), leveraging the Chim-Ad chimeric adenovirus vector platform, PREFER protein refolding technology, and AI-based antigen remodeling. The company reports profitability from 2020 onward, with Q1 2025 molecular diagnostics revenue up 66.5% YoY and Q2 2025 revenue at 27 billion KRW (~$20M USD).

Name

GeneMatrix

Legal name

Genematrix Inc.

Website

https://genematrix.net

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

51–100 employees

Short description

GeneMatrix is a South Korea-based molecular diagnostics company that develops and sells the NeoPlex™ line of proprietary multiplex real-time PCR kits, serving clinical laboratories and hospitals globally across infectious disease, HPV, STI, TB, and respiratory testing, while also advancing a six-candidate vaccine pipeline.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)

akta.pro secondary industries

Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD), Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)

Keywords

• Molecular diagnostics kits
• Multiplex PCR assays
• Infectious disease testing
• Clinical diagnostic reagents
• Vaccine development

Headquarters

HQ city

Seongnam

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Molecular Diagnostic Kits Sales: GeneMatrix generates revenue through the sale of NeoPlex™ multiplex real-time PCR diagnostic kits for infectious disease detection. Products are sold in kit formats (96 tests/kit, 50 tests/kit) to clinical laboratories and healthcare facilities.
2. Biochemical Diagnostic Reagents: Following acquisition of HBI in 2011, the company develops and sells general and special biochemical diagnostic reagents, expanding their product portfolio beyond molecular diagnostics.
3. Vaccine Development: GeneMatrix is developing vaccines for hepatitis A, Japanese encephalitis, herpes zoster, COVID-19, Zika virus, and HPV therapeutic vaccine. Revenue from vaccines would come from commercialization upon regulatory approval.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

GeneMatrix develops and manufactures multiplex real-time PCR diagnostic kits under the NeoPlex™ brand for simultaneous detection of multiple infectious disease pathogens including sexually transmitted infections, HPV, respiratory infections, tuberculosis, and gastrointestinal infections. The company also operates a biochemical diagnostics business under the HiSens™ brand acquired through HBI in 2011, and maintains a development pipeline of vaccine candidates using proprietary platform technologies.

Product overview

GeneMatrix is a molecular diagnostics and vaccine development company offering the NeoPlex™ line of multiplex real-time PCR diagnostic kits and a pipeline of 6 vaccine candidates. The NeoPlex™ product family includes respiratory infection panels (RV-Panel A for 10 viruses, RV-Panel B for 9 viruses, RB-8 for 8 bacteria, FluCOVID and COVID-19 FAST for SARS-CoV-2), TB/NTM-5 for tuberculosis detection, HPV detection kits (HPV29 for 29 types, HPV HR for 14 high-risk types), STI panels (STI-7, STI-7 PLUS, STI-14), and GI-Virus 6 for gastrointestinal pathogens. All NeoPlex™ products utilize the proprietary C-Tag™ single-tube multiplex PCR technology. The vaccine pipeline spans infectious diseases (Hepatitis A, Japanese encephalitis, Herpes zoster, COVID-19, Zika virus) and cancer (HPV therapeutic vaccine), developed using technology platforms including Chim-Ad™ vector, PREFER™ protein technology, and AI-based antigen remodeling.

Differentiator

Problem solved

Functional benefit

Brands

• NeoPlex: Multiplex real-time PCR diagnostic product line for molecular diagnostics including STI, HPV, respiratory infections, tuberculosis, and gastrointestinal infections
• HiSens
• Chim-Ad
• PREFER

Products and services

• NeoPlex™ STI-14 Detection Kit Single-tube multiplex real-time PCR assay for simultaneous detection of 14 sexually transmitted infection-causing pathogens, designed for clinical laboratories performing molecular STI screening.
• NeoPlex™ STI-7 Detection Kit Single-tube multiplex real-time PCR assay for simultaneous detection of 7 major STI-causing pathogens, targeted at clinical laboratories running routine molecular STI screening.
• NeoPlex™ STI-7 PLUS Detection Kit Single-tube multiplex real-time PCR assay for simultaneous detection of 7 additional STI-causing pathogens including Candida albicans and Gardnerella vaginalis, intended for laboratories needing expanded STI coverage including vaginitis-related organisms.
• NeoPlex™ HPV29 Detection Kit Single-tube multiplex real-time PCR assay for simultaneous detection and genotyping of 29 HPV types (21 high-risk, 8 low-risk), used by clinical laboratories for cervical cancer screening and HPV surveillance.
• NeoPlex™ HPV HR Detection Single-tube multiplex real-time PCR assay for simultaneous detection and genotyping of 14 high-risk HPV genotypes, designed for clinical laboratories focused on high-risk HPV screening.
• NeoPlex™ RV-Panel A Detection Kit Single-tube multiplex real-time RT-PCR assay for simultaneous detection of 10 viral respiratory pathogens including Influenza A, Influenza A H1N1 pdm09, Influenza A H3N2, and RSV, intended for clinical laboratories and hospitals performing respiratory infection screening.
• NeoPlex™ RV-Panel B Detection Kit Single-tube multiplex real-time RT-PCR assay for simultaneous detection of 9 viral respiratory pathogens including Coronavirus OC43 and NL63, used by clinical labs running broader viral respiratory panels.
• NeoPlex™ RB-8 Detection Kit Single-tube multiplex real-time PCR assay for simultaneous detection of 8 respiratory bacteria causing pneumonia, pertussis, and other infections, designed for clinical laboratories performing bacterial respiratory screening.
• NeoPlex™ FluCOVID Detection Kit One-step real-time RT-PCR assay for simultaneous detection of SARS-CoV-2, Influenza A and B viruses in a single test, designed for clinical laboratories and hospitals during respiratory virus season.
• NeoPlex™ COVID-19 FAST One-step real-time RT-PCR assay for fast detection of SARS-CoV-2 RdRp and N genes within 45 minutes using TaqMan technology, designed for rapid screening in clinical laboratories and point-of-need settings.
• NeoPlex™ COVID-19 Detection Kit One-step real-time RT-PCR assay for simultaneous detection of SARS-CoV-2 RdRp and N genes, supplied globally including to UNICEF during the COVID-19 pandemic for diagnostic use in clinical laboratories.
• NeoPlex™ TB/NTM-5 Detection Kit Single-tube multiplex real-time PCR assay for simultaneous detection of Mycobacterium tuberculosis and 5 pathogenic NTM species (M. abscessus, M. massiliense, M. avium, M. intracellulare, M. kansasii), intended for clinical laboratories performing mycobacterial screening.
• NeoPlex™ GI-Virus 6 Detection Kit Single-tube multiplex real-time RT-PCR assay for simultaneous detection of 6 gastrointestinal infection-causing pathogens including Norovirus GI and GII, used by clinical laboratories for gastroenteritis screening.
• HiSens™ Biochemical Diagnostic Reagents (Special Chemistry and General Chemistry) General and special biochemical clinical chemistry diagnostic reagents (marketed under the HiSens™ brand, including the HiSens™ Auto RPR LTIA syphilis screening test) sold to clinical laboratories and healthcare facilities for routine chemistry testing.

Quantifiable outcome

• 4X increase in experiment efficiency compared to single-plex testing
• +4 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature7 records

Partnerships

Five partnerships are on record, tiered minor and core.

• Jeonnam Bio Industry Promotion AgencyminorStrategic or Co-development Partner · 21 October 2021Partnership for hepatitis A vaccine efficacy evaluation and GMP production of COVID-19 vaccine candidate. Collaboration established through vaccine commercialization technology development project.
• Kyung Hee UniversityminorStrategic or Co-development Partner · 21 October 2021Joint development of domestically produced hepatitis A vaccine through infectious disease prevention and treatment technology development project awarded by Ministry of Health and Welfare.
• International Vaccine Institute (IVI)coreStrategic or Co-development PartnerGeneMatrix collaborated with IVI, an internationally recognized organization, to conduct efficacy evaluation of COVID-19 vaccine candidate (GM-ChimAd-CV). IVI confirmed excellent cross-protection effects against mutant virus strains including delta variant.
• Korea Disease Control and Prevention AgencycoreStrategic or Co-development PartnerJoint development of Zika virus recombinant vaccine candidate (GMZV-01) along with established vaccine purification and efficacy evaluation system.
• Vaccine Safety Technology Support CenterminorStrategic or Co-development PartnerCollaborative partnership for hepatitis A vaccine efficacy evaluation methodology development as part of national vaccine development initiatives.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Cepheid (Danaher): Global leader in molecular diagnostics with the GeneXpert system and Xpert multiplex test menu (respiratory, STI, HPV, MTB) — represents the dominant platform incumbent that GeneMatrix competes against in clinical lab settings.
• Hologic: Major molecular diagnostics player with the Panther system and Aptima assays for STI, HPV, and respiratory testing — broad incumbent competing with GeneMatrix in women's health and infectious disease molecular testing.
• Roche Diagnostics: Largest global diagnostics player offering cobas molecular systems and broad infectious disease test menus; competes with GeneMatrix for high-volume hospital and reference lab contracts worldwide.
• QIAGEN: Global molecular diagnostics and sample preparation technology provider with QIAstat-Dx multiplex syndromic panels (respiratory, GI) — directly comparable multiplex product offering to GeneMatrix's NeoPlex panels.

Direct peers

• Seegene: Seoul-based molecular diagnostics company specializing in multiplex real-time PCR technology with syndromic panels for respiratory, STI, HPV, and gastrointestinal infections — directly comparable to GeneMatrix's NeoPlex product line in technology and target markets.
• Osang Healthcare (OSANG Healthcare / GC Genome): Korean IVD manufacturer producing molecular diagnostic kits and rapid tests for infectious diseases including COVID-19, respiratory, and STI panels — overlapping with GeneMatrix's syndromic testing menu.
• SolGent: South Korean diagnostic company producing molecular diagnostic reagents and PCR-based kits for infectious diseases, including the DiaPlexQ multiplex product line — directly comparable to GeneMatrix's multiplex PCR positioning.
• Kogene Biotech: Korean molecular diagnostics company offering real-time PCR kits for infectious diseases including respiratory viruses, HPV, and sexually transmitted infections — overlapping product portfolio with GeneMatrix's NeoPlex line.
• Bioneer: Korean molecular diagnostics and life sciences company with PCR-based diagnostic kits and AccuPower product line, serving similar clinical laboratory customers as GeneMatrix in Korea and internationally.

Regional players

• Mestastem (in stem cell space): Listed on KOSDAQ with biotech focus; included as a regional Korean peer reference for comparable valuation dynamics rather than direct product competition, since specific multiplex PCR Korean small-cap peers beyond the named above are limited.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@GeneMatrix
• LinkedInlinkedin.com/company/genematrix

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GeneMatrix